|
EP2012791A2
|
|
7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
|
|
AU2006331917A1
|
|
Orally active purine-based inhibitors of heat shock protein 90
|
|
CN101505762A
|
|
Orally active purine-based inhibitors of heat shock protein 90
|
|
US2007129334A1
|
|
Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
|
|
AU2006320435A1
|
|
Compositions containing ansamycin
|
|
EP1937258A2
|
|
Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
|
|
EP1871361A2
|
|
Phospholipid-based pharmaceutical formulations and methods for producing and using same
|
|
NZ561939A
|
|
Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
|
|
WO2006050457A2
|
|
Methods and compositions for treating chronic lymphocytic leukemia
|
|
US2006067953A1
|
|
Oral pharmaceutical formulations and methods for producing and using same
|
|
AU2004274507A1
|
|
Novel heterocyclic compounds as HSP90-inhibitors
|
|
CN1882589A
|
|
Novel heterocyclic compounds as HSP90-inhibitors
|
|
CA2518836A1
|
|
Drug formulations having long and medium chain triglycerides
|
|
CN1764446A
|
|
Drug formulations having long and medium chain triglycerides
|
|
US2006148776A1
|
|
Drug formulations having long and medium chain triglycerides
|
|
EP1581261A1
|
|
Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
|
|
CA2481683A1
|
|
Ansamycin formulations and methods for producing and using same
|
|
CA2474508A1
|
|
Ansamycins having improved pharmacological and biological properties
|
|
AU2002364566A1
|
|
Assays and implements for determining and modulating HSP90 binding activity
|
|
EP1450784A2
|
|
Hsp90-inhibiting zearalanol compounds and methods of producing and using same
|
